J. Goldman & CO LP Keros Therapeutics, Inc. Transaction History
J. Goldman & CO LP
- $3.27 Billion
- Q2 2024
A detailed history of J. Goldman & CO LP transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, J. Goldman & CO LP holds 30,102 shares of KROS stock, worth $1.7 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
30,102Holding current value
$1.7 Million% of portfolio
0.04%Shares
6 transactions
Others Institutions Holding KROS
# of Institutions
157Shares Held
27.1MCall Options Held
28.7KPut Options Held
1.8K-
Black Rock Inc. New York, NY2.51MShares$142 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.76MShares$99.2 Million0.0% of portfolio
-
Alkeon Capital Management LLC New York, NY1.6MShares$90.3 Million0.12% of portfolio
-
Darwin Global Management, Ltd. St. Helier, Y91.53MShares$86.1 Million8.43% of portfolio
-
Orbimed Advisors LLC San Diego, CA1.27MShares$71.6 Million1.4% of portfolio
About Keros Therapeutics, Inc.
- Ticker KROS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,757,000
- Market Cap $1.45B
- Description
- Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...